Intracerebral-Hemorrhage
DWI-Positive Lesions in Patients With Acute Intracerebral Hemorrhage — Associations With Cerebral Small Vessel Disease and Clinical Outcome
Remote DWI-positive lesions occurred in 21.6% of patients with acute intracerebral hemorrhage and independently marked greater small-vessel-disease burden and worse six-month functional outcome.
Impact of Ultra-Early Perioperative Antihypertensive Therapy in Acute Intracerebral Hemorrhage — INTERACT3 Secondary Analysis
In INTERACT3 surgical-evacuation patients, achieving systolic BP <140 mm Hg within 2 hours was associated with lower death or disability, better mRS shift, fewer serious adverse events, and no increase in mortality.
A Restrictive Versus a Liberal Transfusion Strategy in Patients With Spontaneous Intracerebral Hemorrhage: A Secondary Analysis of TRAIN Randomized Clinical Trial
Secondary analysis of the TRAIN RCT: in 144 anemic ICU patients with spontaneous ICH, a liberal transfusion strategy (Hb <9 g/dL) showed a nonsignificant 13-point absolute reduction in unfavorable 180-day GOS-E versus restrictive (Hb <7 g/dL).
Prior Dual Antiplatelet Therapy and Mortality After Intracerebral Hemorrhage: A Danish Nationwide Cohort Study
A Danish nationwide cohort found that patients with intracerebral hemorrhage who were receiving dual antiplatelet therapy had higher early mortality than those receiving single antiplatelet therapy, although residual confounding and unmeasured hematoma characteristics limit causal interpretation.
Minimally Invasive Surgery vs Medical Management Alone for Intracerebral Hemorrhage — The MIND Randomized Clinical Trial
In the MIND trial, minimally invasive surgery with the Artemis device within 72 hours did not significantly reduce 30-day mortality or improve 180-day disability in supratentorial ICH versus medical management alone.
Deep-Dive: Predictors of Hematoma Expansion and Response to Andexanet — ANNEXA-I Secondary Analyses
ANNEXA-I secondary analyses: andexanet benefit amplifies in highest-risk HE quartiles (NNT ~4) without amplifying thrombotic-event risk; authors propose an 11-to-1 rule.
Deep-Dive: ANNEXA-I Biomarker Substudy — Andexanet's Therapeutic Window Is 1 Hour, and It Cuts Both Ways
ANNEXA-I biomarker substudy: 1-hour reduction in anti-FXa (OR 0.69/100 ng/mL) and rise in ETP (OR 0.94/100 nmol/L-min) both predict fewer hematoma expansions; the ETP rise also independently predicts more thrombotic events (OR 1.08).
Deep-Dive: ACTISAVE — Glenzocimab Fails to Beat Placebo on Top of tPA ± EVT
ACTISAVE failed to confirm a beneficial effect of glenzocimab on mRS in patients with acute ischemic stroke treated by thrombolysis ± thrombectomy.